Drugs / VB11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04406272 | Aug 2020 → Aug 2024 | glioblastoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VB11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04406272 ↗ |
| Known as | VB-111 | “In this research study, ofranergene obadenovec (VB-111) is the investigational drug being studied.” NCT04406272 ↗ |
| Action | Inhibit | “works by blocking the process of blood-vessel creation” NCT04406272 ↗ |
| Route | Intravenous | “Intravenously administered” NCT04406272 ↗ |